Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Analyst consensus "Buy" — Seven analysts rate AAPG a Buy (five Buy, two Strong Buy) with an average 1-year price target of $48.00, roughly double the stock's recent open near $22.34.
• Unprofitable but advancing pipeline — The company reported a quarterly EPS of ($0.52) and is forecast to post -1.09 EPS for the year, while progressing clinical-stage oncology candidates (APG-2575 and APG-115) targeting Bcl‑2 and the MDM2–p53 axis.
• Institutional interest and valuation gap — Multiple institutions (UBS, Citadel, HSBC, Mirae, XY Capital) have added or increased positions, and the stock trades well below its 52-week high of $48.45 with 50- and 200-day SMAs of $24.43 and $28.16 respectively.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) has received an average rating of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $48.00.

AAPG has been the subject of several research analyst reports. China Intl Cap upgraded shares of Ascentage Pharma Group International to a "strong-buy" rating in a research report on Monday, April 6th. BTIG Research reiterated a "buy" rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Finally, Rodman & Renshaw assumed coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a "buy" rating and a $48.00 price objective on the stock.

Ascentage Pharma Group International Stock Performance

Shares of NASDAQ:AAPG opened at $22.34 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. Ascentage Pharma Group International has a 52 week low of $19.11 and a 52 week high of $48.45. The firm has a 50 day simple moving average of $24.43 and a 200 day simple moving average of $28.16.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million for the quarter. Research analysts forecast that Ascentage Pharma Group International will post -1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in Ascentage Pharma Group International in the 3rd quarter valued at approximately $96,000. Citadel Advisors LLC acquired a new position in Ascentage Pharma Group International in the 3rd quarter valued at approximately $383,000. Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International in the 2nd quarter valued at approximately $391,000. UBS Group AG increased its stake in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company's stock valued at $716,000 after buying an additional 10,988 shares during the period. Finally, XY Capital Ltd increased its stake in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company's stock valued at $707,000 after buying an additional 12,530 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.